Stock ENTO ENTERO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Entero Therapeutics, Inc.

Equities

ENTO

US33749P4081

Delayed Nasdaq
Other stock markets
 02:43:40 2024-06-14 pm EDT 		5-day change 1st Jan Change
2.17 USD -1.37% Intraday chart for Entero Therapeutics, Inc. -11.16% -48.34%
May. 20 Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index CI
May. 17 First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc CI

Evolution of the average Target Price on Entero Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

082162e6eedd61a1dccbfe38b2d62a5.HhYEFzkD_CD5bVlrOTqQ8U99m0Qd8YJ14-sfc_HdpJ4.am9HeklzmlGrAiwxcAmkhwsp3D5km-4jp44oMb6Kw_x_RUJlbTuPVrUuKg~5c252d85613e548ae58ca5b8faed3425

Analyst Recommendations on Entero Therapeutics, Inc.

HC Wainwright Downgrades First Wave BioPharma to Neutral From Buy MT
May CPI Inflation Slows in Line With Analysts' Expectations, Driving Narrow Premarket Gains for US Equity Futures MT
HC Wainwright Adjusts First Wave BioPharma Price Target to $10 From $14, Maintains Buy Rating MT
HC Wainwright Adjusts First Wave BioPharma Price Target to $14 From $18, Maintains Buy Rating MT
HC Wainwright Reiterates First Wave BioPharma at Buy With $18 Price Target MT
HC Wainwright Adjusts First Wave BioPharma's Price Target to $4 From $8, Keeps Buy Rating MT
Roth Capital Adjusts First Wave BioPharma's Price Target to $9 from $20, Keeps Buy Rating MT
Maxim Downgrades First Wave BioPharma to Hold From Buy MT
AZURRX BIOPHARMA : Roth Capital Adjusts Price Target on AzurRx BioPharma to $5 From $7, Maintains Buy Rating MT
AZURRX BIOPHARMA : HC Wainwright Adjusts Price Target on AzurRx BioPharma to $2.50 From $3.50, Maintains Buy Rating MT
AZURRX BIOPHARMA : HC Wainwright Adjusts Price Target on AzurRx BioPharma to $3.50 From $2, Reiterates Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.2 USD
Average target price
36 USD
Spread / Average Target
+1,536.36%
High Price Target
36 USD
Spread / Highest target
+1,536.36%
Low Price Target
36 USD
Spread / Lowest Target
+1,536.36%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Entero Therapeutics, Inc.

HC Wainwright
Roth Capital Partners
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ENTO Stock
  4. Consensus Entero Therapeutics, Inc.